Fig. 4: c-MYC activates the transcription of USP39 in ovarian cancer cells.

A Relative expression of USP39 in ovarian cancer cells with c-MYC overexpression (c-MYC) or knock down (sh-c-MYC) compared to corresponding control (n = 3 biologically independent samples) was measured by qPCR. B Western blot analysis of c-MYC and USP39 protein levels upon c-MYC overexpression or knockdown. C Schematic diagram of the USP39 promoter (−619–+527) constructs based on the PGL4.26 vector. Wild type (wt) and Mutant (mut) refer to the wild-type and mutant versions of the predicted c-MYC binding site. D Luciferase activity was measured in HEK293T cells transfected with a c-MYC overexpression plasmid in combination with a pGL4 plasmid containing the wt or mut promoter region (n = 3 biologically independent samples). E Analysis of c-MYC binding peaks on USP39 promoter region in several cell lines based on ChIP-seq data in Cistrome Data Brower. F, G qPCR and semi-quantitative PCR analysis of ChIP samples from experiments performed in HEY cells using the c-MYC antibody or IgG. Ch16q22, an intergenic sequence, served as negative control. P value was obtained by Student’s t-test. Results represent the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.